NO2825156T3 - - Google Patents

Info

Publication number
NO2825156T3
NO2825156T3 NO13710293A NO13710293A NO2825156T3 NO 2825156 T3 NO2825156 T3 NO 2825156T3 NO 13710293 A NO13710293 A NO 13710293A NO 13710293 A NO13710293 A NO 13710293A NO 2825156 T3 NO2825156 T3 NO 2825156T3
Authority
NO
Norway
Application number
NO13710293A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2825156T3 publication Critical patent/NO2825156T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D475/00Heterocyclic compounds containing pteridine ring systems
    • C07D475/02Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO13710293A 2012-03-16 2013-03-11 NO2825156T3 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12001803 2012-03-16
EP13710293.5A EP2825156B1 (en) 2012-03-16 2013-03-11 Targeting aminoacid lipids
PCT/EP2013/000698 WO2013135359A1 (en) 2012-03-16 2013-03-11 Targeting aminoacid lipids

Publications (1)

Publication Number Publication Date
NO2825156T3 true NO2825156T3 (hu) 2017-12-23

Family

ID=47901004

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13710293A NO2825156T3 (hu) 2012-03-16 2013-03-11

Country Status (21)

Country Link
US (2) US9878044B2 (hu)
EP (1) EP2825156B1 (hu)
JP (2) JP6527331B2 (hu)
KR (2) KR102208586B1 (hu)
CN (1) CN104168888A (hu)
AU (2) AU2013231638B2 (hu)
BR (1) BR112014022451B1 (hu)
CA (1) CA2867169C (hu)
DK (1) DK2825156T3 (hu)
ES (1) ES2644778T3 (hu)
HK (1) HK1198924A1 (hu)
IL (1) IL234550A (hu)
MX (1) MX354811B (hu)
NO (1) NO2825156T3 (hu)
NZ (1) NZ631034A (hu)
PT (1) PT2825156T (hu)
RU (1) RU2654210C2 (hu)
SG (2) SG10201610401XA (hu)
TW (1) TWI586370B (hu)
WO (1) WO2013135359A1 (hu)
ZA (1) ZA201407490B (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5539649B2 (ja) 2005-12-13 2014-07-02 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 細胞移植のための足場
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B1 (en) 2010-10-01 2020-12-30 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
LT2624873T (lt) 2010-10-06 2020-03-10 President And Fellows Of Harvard College Įšvirkščiami, poras sudarantys hidrogeliai, skirti medžiagų pagrindo ląstelių terapijai
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013249366B2 (en) 2012-04-16 2018-02-01 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 低密度リポタンパク質受容体をコードするポリヌクレオチド
EP4023249A1 (en) 2014-04-23 2022-07-06 ModernaTX, Inc. Nucleic acid vaccines
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
JP2018532990A (ja) * 2015-09-04 2018-11-08 オービーアイ ファーマ,インコーポレイテッド グリカンアレイおよび使用の方法
HUE057613T2 (hu) 2015-09-17 2022-05-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
CN105505382B (zh) * 2015-12-04 2017-06-27 安徽师范大学 一种铜纳米簇溶液的制备方法及应用
SI3386484T1 (sl) 2015-12-10 2022-06-30 Modernatx, Inc. Sestave in metode za dovajanje terapevtskih sredstev
HUE057877T2 (hu) 2015-12-22 2022-06-28 Modernatx Inc Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
SG11201809024UA (en) 2016-04-22 2018-11-29 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
SG11201810256XA (en) 2016-05-18 2018-12-28 Modernatx Inc Polynucleotides encoding relaxin
CN115404196A (zh) * 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CA3032049C (en) 2016-07-27 2023-11-07 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
TWI786054B (zh) 2016-07-29 2022-12-11 台灣浩鼎生技股份有限公司 人類抗體、醫藥組合物、及其方法
WO2018035388A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US20200283743A1 (en) * 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018038549A1 (ko) * 2016-08-24 2018-03-01 울산대학교 산학협력단 Dtbp를 이용한 미생물 농축 또는 핵산 추출 방법
US11584924B2 (en) 2016-08-24 2023-02-21 Infusion Tech Method for concentrating microorganism or extracting nucleic acid using DTBP
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
AU2017361549B2 (en) 2016-11-21 2023-12-21 Obi Pharma, Inc. Conjugated biological molecules, pharmaceutical compositions and methods
DE17829597T1 (de) * 2016-11-30 2019-12-05 Noxxon Pharma Ag Verfahren zur polyalkoxylierung von nukleinsäuren zur rückgewinnung und wiederverwendung einer überschüssigen polyalkoxylierungsreagenz
WO2018170336A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
HRP20230063T1 (hr) 2017-03-15 2023-03-17 Modernatx, Inc. Spoj i pripravci za intracelularnu isporuku terapijskih sredstava
DK3596042T3 (da) 2017-03-15 2022-04-11 Modernatx Inc Krystalformer af aminolipider
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
JP7275111B2 (ja) 2017-08-31 2023-05-17 モデルナティエックス インコーポレイテッド 脂質ナノ粒子の生成方法
CN111565706A (zh) * 2017-11-09 2020-08-21 免疫疫苗技术公司 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
WO2020182807A1 (en) 2019-03-13 2020-09-17 Merck Patent Gmbh Process for the preparation of lipidated proteinaceous structures
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US4144034A (en) * 1978-03-27 1979-03-13 Texaco Inc. Polyether-maleic anhydride reaction product containing motor fuel composition
EP0142010B1 (de) 1983-11-10 1987-12-23 Hoesch Aktiengesellschaft Verfahren und Vorrichtung zum elektrolytischen Abscheiden von Metallen
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6030954A (en) 1991-09-05 2000-02-29 University Of Connecticut Targeted delivery of poly- or oligonucleotides to cells
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
IT1254135B (it) 1992-01-16 1995-09-08 Sigma Tau Ind Farmaceuti Esteri di acil carnitine con alcooli alifatici a lunga catena e composizioni farmaceutiche che li contengono, ad attivita' antibatterica.
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
EP1173600A2 (en) * 1999-04-20 2002-01-23 The University Of British Columbia Cationic peg-lipids and methods of use
WO2001022995A1 (en) 1999-09-30 2001-04-05 Novo Nordisk A/S A method for preparing conjugates between an antigen and mucosal binding component
JP4678967B2 (ja) * 2001-03-08 2011-04-27 本田技研工業株式会社 ゲル化性有機化合物及びそれを用いるゲル
GB0106041D0 (en) * 2001-03-12 2001-05-02 Cancer Res Ventures Ltd Lipids and liposomes
EP3231445A1 (en) 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
JP5093547B2 (ja) * 2001-08-24 2012-12-12 日本ケミカルリサーチ株式会社 両イオン性脂質およびその用途
US20030138490A1 (en) 2001-09-08 2003-07-24 Zhibing Hu Synthesis and uses of polymer gel nanoparticle networks
EP1308167A1 (de) 2001-11-06 2003-05-07 Pickl, Winfried, Ao. Univ. Prof. Dr. Antigenpräsentierende Vesikel
JP4331927B2 (ja) * 2002-08-29 2009-09-16 協立化学産業株式会社 無機ナノ粒子−有機化合物複合体およびそれの一次元配列集積構造体
WO2004111192A2 (en) * 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
EP1793868B1 (en) 2004-09-23 2010-12-29 Guerbet Liposomal contrast agents for cest imaging
US20100028450A1 (en) 2006-01-25 2010-02-04 The Board Of Trustees Of The University Of Illinoi S Tolerogenic biodegradable artificial antigen presenting system
WO2009129387A2 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
US20100104629A1 (en) 2008-04-16 2010-04-29 Abbott Laboratories Cationic lipids and uses thereof
US20090285881A1 (en) * 2008-04-16 2009-11-19 Abbott Laboratories Cationic lipids and uses thereof
RU2409587C2 (ru) * 2009-03-04 2011-01-20 Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" 1-гексадецил-5-(1-пиренбутил)-n-(l-орнитил)-l-глутамат бисхлорид
ES2694556T3 (es) 2010-09-02 2018-12-21 The Scripps Research Institute Entrega de fármaco a base de nanopartículas focalizada en un tumor
WO2012148891A1 (en) * 2011-04-29 2012-11-01 Evonik Degussa Corporation Peptide-lipid conjugates and uses thereof
SI2825157T1 (sl) * 2012-03-16 2019-01-31 Merck Patent Gmbh Aminokislinski lipidi

Also Published As

Publication number Publication date
BR112014022451A2 (pt) 2017-06-20
ES2644778T3 (es) 2017-11-30
JP2018141015A (ja) 2018-09-13
MX2014010808A (es) 2014-12-05
JP6527331B2 (ja) 2019-06-05
AU2018200293B2 (en) 2019-04-18
MX354811B (es) 2018-03-22
RU2014141545A (ru) 2016-05-10
WO2013135359A1 (en) 2013-09-19
KR102208586B1 (ko) 2021-01-28
AU2018200293A1 (en) 2018-02-01
TWI586370B (zh) 2017-06-11
PT2825156T (pt) 2017-11-02
KR20200036033A (ko) 2020-04-06
SG10201610401XA (en) 2017-01-27
AU2013231638B2 (en) 2017-10-12
US20180133334A1 (en) 2018-05-17
JP2015518463A (ja) 2015-07-02
US11510988B2 (en) 2022-11-29
AU2013231638A1 (en) 2014-10-30
NZ631034A (en) 2016-06-24
EP2825156B1 (en) 2017-07-26
DK2825156T3 (en) 2017-10-30
HK1198924A1 (en) 2015-06-19
ZA201407490B (en) 2015-12-23
TW201343183A (zh) 2013-11-01
US9878044B2 (en) 2018-01-30
SG11201405552VA (en) 2014-10-30
RU2654210C2 (ru) 2018-05-17
IL234550A (en) 2016-12-29
BR112014022451B1 (pt) 2022-06-28
EP2825156A1 (en) 2015-01-21
WO2013135359A8 (en) 2014-07-03
CA2867169C (en) 2021-07-06
BR112014022451A8 (pt) 2021-06-15
KR20140134710A (ko) 2014-11-24
US20150030669A1 (en) 2015-01-29
CA2867169A1 (en) 2013-09-19
CN104168888A (zh) 2014-11-26

Similar Documents

Publication Publication Date Title
BR112015012238A2 (hu)
NO2825156T3 (hu)
BR112014017635A2 (hu)
BR112014017592A2 (hu)
BR112014017659A2 (hu)
BR112014017646A2 (hu)
BR112014017638A2 (hu)
AR092201A1 (hu)
BR112014018745A2 (hu)
BR112014019483A2 (hu)
BR112014019469A2 (hu)
BR112013027865A2 (hu)
BR112014017634A2 (hu)
BR112014017644A2 (hu)
BR112014017647A2 (hu)
BR112014017588A2 (hu)
BR112014022171A2 (hu)
BR112014013184A8 (hu)
BR112014017652A2 (hu)
BR112014017641A2 (hu)
BR112014017631A2 (hu)
BR112014018505A2 (hu)
BR112014017636A2 (hu)
BR112014017667A2 (hu)
BR112014017671A2 (hu)